Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Demonstrate the potential of pharmaceuticals, biotechnology products, medical devices and care delivery patterns on patient health outcomes, medical costs, productivity and quality of life
Identify and quantify key cost drivers to develop efficient, evidence-based estimates for reimbursement and prospective payment
Healthcare Pricing Models
Develop the optimal new drug price and market entry strategy
Market Entry Analysis
Receive continuous analysis, data and online tools covering technology, reimbursement, regulations, geographic/therapeutic segment scenarios
Partner with us for customized research on business improvement and opportunity maximization strategies
Access customized research at less cost by participating in multi-client, syndicated market research that employs qualitative and quantitative surveys, market access scenarios and market analysis
Integrating HTA Requirements into Oncology R&D Process
A pharmaceutical company needed recommendations for incorporating more HTA considerations into R&D decision-making.
We researched recent HTA decisions in Australia, US, United Kingdom, France, Germany, Italy and Spain in the client’s four therapeutic areas. Our detailed case studies identified the choice of trial design, trial comparator, patient group selection, primary and secondary outcome measures, strength of correlation between surrogate and final outcomes, traits of PRO evidence and studies, and a definition of clinical relevance.
We helped the client build user-friendly HTA "checklists". The client uses these checklists to ensure its R&D personnel factor HTA considerations into future planning.
Millions of lives are saved by blood transfusions and this company plays a vital role in making transfusions safe. To provide hospitals with the best pre-transfusion diagnostic products, its researchers are identifying next-generation concepts and generating important innovations while also resolving problems and documenting their findings more efficiently.
A top manufacturer of medical supplies reduced commodity costs by millions of dollars within 18-20 months and enabled its team to negotiate better rates – e.g., pushing back on 6 commodity cost increases in 8 months due to more accurate pricing data. Enabling tighter forecasts and improving workflows helps the company serve consumers more effectively.
This healthcare industry leader maximized productivity by providing 400 users worldwide with 24x7 access to life science/economic data and expanding customized pricing data extracts for 1000s of drugs in 46 markets. When the firm reduced costs by cutting other servics, it continued business intelligence investments that had grown 800% over 10 years.Learn More About Our Customers Success
One of the world’s top suppliers of medical diagnosis technologies met tight US OSHA and EU GHS compliance deadlines – and maintained access to key markets – by reassessing 3,500 reagents according to new GHS classifications and updating 70,000 Safety Data Sheets as well as creating SDSs in 20 unique language formats.Learn More About Our Customers Success
Hurdles encountered in transferability of health economic evidence to middle- and low-income countries https://t.co/3yr2eYMHAY
Two Sides of the Same Coin: National Health Economic Guidelines in Italy and Portugal https://t.co/NX0Ci2z6PJ
Big dreams versus cost-saving schemes – will the UK dare to pursue its Accelerated Access ambitions in… https://t.co/sfgV6jHLnI
The Access to Medicine Index 2016: Highlighting the role for tiered pricing https://t.co/TscP5WXsV3
Follow Life Sciences Consulting @IHS4LifeScience